709655-26-5 Suppliers

Recommended suppliersmore

709655-26-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 709655-26-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,0,9,6,5 and 5 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 709655-26:
(8*7)+(7*0)+(6*9)+(5*6)+(4*5)+(3*5)+(2*2)+(1*6)=185
185 % 10 = 5
So 709655-26-5 is a valid CAS Registry Number.

709655-26-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name	N-{2'-[(tert-butylamino)sulfonyl]-1,1'-biphenyl-4-yl}-1-(3-cyano-4-isopropylideneaminooxyphenyl)-3-methyl-1H-pyrazole-5-carboxamide

1.2 Other means of identification

Product number	-
Other names	2-(3-Cyano-4-isopropylideneaminooxy-phenyl)-5-methyl-2H-pyrazole-3-carboxylic acid (2'-tert-butylsulfamoyl-biphenyl-4-yl)-amide

1.3 Recommended use of the chemical and restrictions on use

Identified uses	For industry use only.
Uses advised against	no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number	-
Service hours	Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:709655-26-5 SDS

709655-26-5Upstream product

709655-26-5Downstream Products

218297-95-1 1-(3'-aminobenzisoxazol-5'-yl)-3-methyl-5-[(2'-aminosulfonyl-[1,1']-biphen-4-yl)aminocarbonyl]pyrazole

709655-26-5Relevant articles and documents

Structure-based design of novel guanidine/benzamidine mimics: Potent and orally bioavailable factor Xa inhibitors as novel anticoagulants

Lam, Patrick Y. S.,Clark, Charles G.,Li, Renhua,Pinto, Donald J. P.,Orwat, Michael J.,Galemmo, Robert A.,Fevig, John M.,Teleha, Christopher A.,Alexander, Richard S.,Smallwood, Angela M.,Rossi, Karen A.,Wright, Matthew R.,Bai, Stephen A.,He, Kan,Luettgen, Joseph M.,Wong, Pancras C.,Knabb, Robert M.,Wexler, Ruth R.

, p. 4405 - 4418 (2007/10/03)

As part of an ongoing effort to prepare orally active factor Xa inhibitors using structure-based drug design techniques and molecular recognition principles, a systematic study has been performed on the pharmacokinetic profile resulting from replacing the

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 709655-26-5

CAS

709655-26-5